POST Online Media Lite Edition


Pfizer steps back from $150 billion takeover of Allergan

Staff writer |
Pfizer as decided to kill its planned $150 billion takeover of Allergan after the Obama administration took aim at a deal that would have moved the biggest drug company in the U.S. to Ireland to lower its taxes, according to people familiar with the matter.

Article continues below

The companies are expected to announce the deal’s termination as early as Wednesday morning, after Pfizer’s board voted Tuesday to halt the combination and the New York-based pharmaceutical company then notified Allergan, the people said.

Pfizer will pay Allergan a small breakup fee, the people said. The merger agreement called for a fee covering Allergan’s integration-planning expenses of up to $400 million in the event that tax rule-changes rendered the deal unworkable.

Late Tuesday, the sides were still working out how much the planning had cost Allergan, but it is expected to be much less than the full $400 million, one of the people said.

Read the whole story on " class="companylink"> The Wall Street Journal.

What to read next

Pfizer thinking about consumer healthcare business sale
Pfizer completes Hospira acquisition
Pfizer to sell infusion business to ICU Medical